La FDA aprobó Itvisma para tratar a los pacientes con AME de 2 años y mayores.👧🧒

🔗Lee el artículo completo en el siguiente link: lnkd.in/e4Dg2bWJ

#TheAkariFounation #enfermedadesraras #AtrofiaMuscularEspinal #AME #Itvisma #Novartis

Gene Therapy And A New Era Of Neuroscience - Dr. #NormanPutzki MD - SVP, Global Clinical Development Head, U.S. Development Site Head, #Novartis joins me on Progress, Potential, And Possibilities #GeneTherapy #Neuroscience #SpinalMuscularAtrophy #Zolgensma #Itvisma - www.youtube.com/watch?v=f2hN...

Orsini Partners with ITVISMA® to Enhance Treatment Options for SMA Patients Orsini has been announced as a specialty pharmacy partner for ITVISMA®, a groundbreaking gene therapy for spinal muscular atrophy, expanding treatment options for patients aged two and older.

Orsini Partners with ITVISMA® to Enhance Treatment Options for SMA Patients #United_States #Elk_Grove_Village #Orsini #Itvisma #SMA_Treatment

Novartis' Itvisma® Receives FDA Approval for SMA Treatment: A Milestone for Gene Therapy Novartis' Itvisma®, the first gene replacement therapy for spinal muscular atrophy (SMA), has been approved by the FDA for patients aged two and older, marking a significant breakthrough.

Novartis' Itvisma® Receives FDA Approval for SMA Treatment: A Milestone for Gene Therapy #USA #SMA #Novartis #East_Hanover #Itvisma